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Strengths and limitations of this study
 ► This study used a lung cancer screening- specific 
questionnaire with high content validity and ade-
quate psychometric properties to measure the psy-
chosocial consequences of the screening results.
 ► In addition to the false- positive group, the true- 
positive group and the true- negative group were 
assessed, serving as benchmarks against which 
to compare the psychosocial consequences in the 
false positives.
 ► A limitation is that the control group, who were not 
invited to screening, reported more negative psy-
chosocial consequences than the screening group.
 ► Another limitation is that the study participants had 
a more robust psychosocial profile compared with a 
matched background population.
AbStrACt
Objectives Lung cancer CT screening can reduce lung 
cancer mortality, but high false- positive rates may cause 
adverse psychosocial consequences. The aim was to 
analyse the psychosocial consequences of false- positive 
lung cancer CT screening using the lung cancer screening- 
specific questionnaire, Consequences of Screening in Lung 
Cancer (COS- LC).
Design and setting This study was a matched cohort 
study, nested in the randomised Danish Lung Cancer 
Screening Trial (DLCST).
Participants Our study included all 130 participants in the 
DLCST with positive CT results in screening rounds 2–5, 
who had completed the COS- LC questionnaire. Participants 
were split into a true- positive and a false- positive group 
and were then matched 1:2 with a control group (n=248) 
on sex, age (±3 years) and the time of screening for the 
positive CT groups or clinic visit for the control group. 
The true positives and false positives were also matched 
1:2 with participants with negative CT screening results 
(n=252).
Primary outcomes Primary outcomes were psychosocial 
consequences measured at five time points.
results False positives experienced significantly more 
negative psychosocial consequences in seven outcomes at 1 
week and in three outcomes at 1 month compared with the 
control group and the true- negative group (mean ∆ score >0 
and p<0.001). True positives experienced significantly more 
negative psychosocial consequences in one outcome at 1 
week (mean ∆ score 2.86 (95% CI 1.01 to 4.70), p=0.0024) 
and in five outcomes at 1 month (mean ∆ score >0 and 
p<0.004) compared with the true- negative group and the 
control group. No long- term psychosocial consequences 
were identified either in false positives or true positives.
Conclusions Receiving a false- positive result in lung 
cancer screening was associated with negative short- term 
psychosocial consequences. These findings contribute to 
the evidence on harms of screening and should be taken 
into account when considering implementation of lung 
cancer screening programmes.
trial registration number NCT00496977.
IntrODuCtIOn
Lung cancer has the highest mortality 
worldwide.1 Several randomised controlled 
screening trials using low- dose CT scans have 
investigated the effect of CT screening on 
lung cancer- specific mortality.2 The largest 
trial, the National Lung Screening Trial 
(NLST), found a relative lung cancer- specific 
mortality reduction of 16% after 5- year 
follow- up, and lung cancer CT screening is 
now recommended in the USA.3–5 However, 
according to a Cochrane systematic review, 
more data are needed on false- positive results 
and overdiagnosis before recommendations 
can be made for large- scale CT- screening 
programmes.6 The Danish Lung Cancer 
Screening Trial (DLCST) could not show 
a reduction in lung cancer- specific or total 
mortality after a 5- year follow- up.7 The Euro-
pean trials are expected to publish the pooled 
follow- up analyses of both the mortality data 
and the consequences of overdiagnosis and 
false- positive results.8 This will provide the 
additional evidence of benefits and harms of 
lung cancer CT screening requested in the 
Cochrane systematic review.6
Protected by copyright.
 o
n
 Septem
ber 6, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034682 on 4 June 2020. Downloaded from 
2 Rasmussen JF, et al. BMJ Open 2020;10:e034682. doi:10.1136/bmjopen-2019-034682
Open access 
Figure 1 Distribution of screening results and final diagnoses in the DLCST, and response rates of the matched groups at five 
time points: baseline, 1 week, 1, 6 and 18 months. COS- LC, Consequences of Screening in Lung Cancer; DLCST, Danish Lung 
Cancer Screening Trial.
In cancer screening programmes, positive screening 
results lead to either false- positive results or true- positive 
results after further diagnostic workup.9 A false- positive 
screening result can cause both physical and psychoso-
cial harms10–13 as well as being costly for the healthcare 
system.14–16 The average false- positive rate per screening 
round varies substantially in lung cancer screening trials, 
for example, 23% in the NLST and 3% in the DLCST 
(online supplementary appendix 1).3 17 Qualitative and 
quantitative studies have shown that false- positive lung 
cancer screening results can be associated with negative 
psychosocial consequences both during workup and 
after the final diagnosis.13 18 19 By their nature, qualita-
tive studies cannot measure the degree or the extent of 
psychosocial consequences,18 and all the published quan-
titative studies used generic questionnaires which lack 
content validity and have unknown psychometric prop-
erties.13 19–21 Measurement of the psychosocial conse-
quences of screening using questionnaires with high 
content validity and adequate psychometric properties is 
important.22
The aim of this study, therefore, was to measure the 
short- term and long- term psychosocial consequences 
of false- positive lung cancer CT screening results using 
the questionnaire Consequences of Screening in Lung 
Cancer (COS- LC) and to compare these scores with the 
COS- LC scores from three other groups of participants 
in the DLCST: 1) the true- negative group, 2) the true- 
positive group and 3) a control group that did not partic-
ipate in screening.
MethODS
Study design and participants
The overall design of the DLCST has been reported in 
detail elsewhere.17 23 In summary, the DLCST was a single- 
centre, randomised controlled trial and participants were 
randomly allocated to a CT group and a control group 
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(figure 1). Eligible participants were current and former 
smokers with a smoking history of minimum 20 ciga-
rettes/day for 20 years, and were aged 50–70 years.17 23 
In five rounds between 2004 and 2010, both groups were 
offered annual spirometry and smoking counselling 
and were asked to complete the COS- LC questionnaire. 
Participants in the CT group were also offered annual 
lung CT scans.
This study was a matched cohort study nested in the 
DLCST. Participants from the CT group with positive 
CT screening results during rounds 2–5 were matched 
1:2 with participants with negative CT screening results, 
and 1:2 with participants from the control group. Partic-
ipants were matched on sex, age (±3 years) and the time 
of screening, within 7 days for the CT group, or clinic 
visit for the control group. The group with positive CT 
screening results was further divided into a true- positive 
group and a false- positive group after receiving the final 
diagnosis. Participants completed the COS- LC at five time 
points (figure 1):
 ► Baseline: COS- LC was completed shortly before 
the annual CT screening (CT group) or clinic visit 
(control group).
 ► One week after receiving the CT screening result 
(CT group) and 1 week after the annual clinic visit 
(control group).
 ► 1, 6 and 18 months after receiving the final diagnosis 
of the screening result (CT group) and at these time 
points after the annual clinic visit (control group).
At the latter four time points, participants were sent 
the COS- LC by post and asked to return it in an enclosed 
stamped addressed envelope. A reminder was sent to 
participants who did not return the COS- LC within 2 
weeks.
Information about region of residence, smoking status, 
smoking history, social group, employment status, school 
education and whether participants lived alone was 
obtained from baseline and annual questionnaires. The 
Charlson Comorbidity Index was calculated from hospital 
admissions 3 years before baseline.
Questionnaire
The COS- LC is a condition- specific questionnaire with 
high content validity and adequate psychometric prop-
erties and it was developed and validated to measure 
the psychosocial consequences of participation in lung 
cancer CT screening.18 To ensure high content validity, 20 
participants from the first screening round in the DLCST 
were interviewed in five group interviews.18 Subsequently, 
during screening rounds 2–4 in the years 2006–2007, ques-
tionnaire data from participants were used to validate the 
COS- LC using Item Response Theory Rasch models.18 As 
these data were only a part of the present data, the psycho-
metric properties of the 15 COS- LC scales were re- tested 
for homogeneity and differential item functioning (DIF) 
relative to participant group, sex, age, social status and 
smoking status by using likelihood ratio tests on appropri-
ately conditioned Rasch models at the 1 month follow- up 
time point.24 Reliability of the scales was examined using 
Cronbach’s alpha.
The COS- LC has two parts where part I encompasses 24 
COS items (4 COS scales) and 25 lung cancer screening- 
specific items (5 lung cancer screening- specific scales) 
(online supplementary appendix 2). Part I can be used 
before, during and after screening and the DLCST 
participants in both the CT group and the control group 
completed part I.18 The higher the scale score, the more 
negative the psychosocial consequences.18
Part II measures the long- term psychosocial conse-
quences after lung cancer CT screening and can there-
fore only be completed by the screening participants (CT 
group) after they have received their final diagnosis.18
Part II encompasses 24 items (6 scales) and was 
designed and validated to measure changes, both positive 
and negative; high scores denote more change (online 
supplementary appendix 2).
Statistical analysis
The differences in the characteristics of the four groups 
of participants (true- negative, true- positive, false- positive 
and control) were tested with Pearson’s χ2 tests for cate-
gorical variables and Kruskal- Wallis non- parametric tests 
for continuous variables.
For each of the 15 COS- LC scales, the mean score 
for each of the four participant groups at the five time 
points was analysed with linear regression models, both 
unadjusted and adjusted for the participant characteris-
tics: round, sex, (a quadratic function of) age, region, (a 
quadratic function of) pack years, smoking status, social 
group, living alone, employment status, school education 
and Charlson Comorbidity Index. Generalised estimating 
equations were used to account for repeated measure-
ment. To adjust for differential dropout, the non- missing 
scales at each time point were weighted by the inverse 
of the probability of this scale being observed at that 
time.25 These probabilities were estimated from the data 
in logistic regression models for the scale being missing, 
which included the participant characteristics, the partic-
ipant groups and the corresponding scale outcomes from 
previous time points.
The statistical level of significance was set using the 
method of Benjamini- Hochberg to adjust for multiple 
testing.26 Statistical Analysis Software V.9.3 was used to 
analyse the data.
Participant and public involvement
DLCST participants were involved in the development of 
the questionnaire COS- LC. Neither participants nor the 
Danish general public were involved in the design and 
recruitment of the study.
reSultS
Participation
Distribution of final diagnostic results and participa-
tion rates are presented in figure 1. In rounds 2–5, 193 
Protected by copyright.
 o
n
 Septem
ber 6, 2020 at Kobenhavns Universitets Bibliotek.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034682 on 4 June 2020. Downloaded from 
4 Rasmussen JF, et al. BMJ Open 2020;10:e034682. doi:10.1136/bmjopen-2019-034682
Open access 
participants received a positive screening result; of those, 
130 (67%) completed the COS- LC and were included in 
this study. The reasons for non- response were: 1) never 
receiving the COS- LC because the participant contact 
details were not available to the researchers (n=39, 20%), 
2) declining to complete the COS- LC (n=6, 3%); and 3) 
other reasons (n=18, 9%).
Of the 130 respondents included in the study, 24 (19%) 
had received one false- positive result in the previous 
rounds and one (0.8%) had previously received two false- 
positive results. The COS- LC was sent to 252 participants 
with true- negative results and 248 control participants. 
Response rates for the four groups during the five time 
points were 64%–97% (figure 1).
There was a significant difference between the four 
groups regarding age and smoking history: the partic-
ipants in the true- positive group were older and had a 
longer smoking history (table 1). A significant difference 
was also observed in the region of residence, where false 
positives, to a greater extent, lived outside the capital 
region compared with the other groups. No significant 
differences were found in the remaining participant 
characteristics.
The 15 COS- LC scales exhibited overall adequate fit to 
the partial credit Rasch model for polytomous items. No 
DIF was revealed and Cronbach’s alpha was 0.693–0.962 
(table 2).
COS-lC part I
Figure 2 presents the mean score of the nine outcomes 
for COS- LC part I for the four groups at the five time 
points. For part I in general, participants with a positive 
CT screening result reported more negative psychoso-
cial consequences at the short- term follow- up points of 
1 week and 1 month (figure 2). The false- positive group 
experienced significantly more negative psychosocial 
consequences at 1 week in seven outcomes (anxiety, 
behaviour, dejection, self- blame, focus on airway symp-
toms, introvert and harm of smoking) and at 1 month 
in three outcomes (self- blame, focus on airway symptoms 
and harm of smoking) (mean ∆ score >0 and p<0.001) 
compared with both the control group and the true- 
negative group (figure 2, online supplementary appendix 
3). At 6 and 18 months, there was a trend towards more 
negative psychosocial consequences in three outcomes, 
but no statistically significant differences were found. 
The true- positive group showed the same general pattern 
and experienced significantly more negative psychosocial 
consequences only in the outcome dejection at 1 week 
(mean ∆ score 2.86 (95% CI 1.01 to 4.70), p=0.0024) and 
in the three outcomes behaviour, dejection and focus 
on airway symptoms at 1 month (mean ∆ score >0 and 
p<0.004) compared with the true- negative group and the 
control group (figure 2, online supplementary appendix 
3). At baseline, the true- positive group showed a signifi-
cantly more positive psychosocial profile in the outcomes 
anxiety and self- blame.
COS-lC part II
Figure 3 presents the mean scores of the six outcomes 
for COS- LC part II for the three groups at the three 
follow- up points after receiving the final screening result. 
The false- positive group showed a trend towards more 
psychosocial consequences in two outcomes at 1 month 
compared with the true- negative group, but no significant 
differences were seen. The true- positive group showed 
significant differences in the outcome social network at 
1 month and 6 months and in the outcome empathy at 
1 month (figure 3, online supplementary appendix 3). 
Trends towards more psychosocial consequences were 
seen in five outcomes at 1 month compared with the true- 
negative group. This difference diminished at 6 and 18 
months. The true- negative group showed no variation in 
psychosocial consequences through the three long- term 
follow- up points.
DISCuSSIOn
False- positive lung cancer CT screening results were associ-
ated with negative short- term psychosocial consequences 
compared with the control group and the true- negative 
group. There were no identified long- term consequences 
of false- positive results. Contrary to expectation, neither 
were there any long- term consequences experienced by 
the true- positive group.
The tendency towards more negative long- term psycho-
social consequences in the false- positive group was 
limited to three lung cancer- specific scales in part I of 
COS- LC. The same pattern was seen for the true- positive 
group. Additionally, this group reported more psycho-
social consequences in the scales Social Network and 
Empathy in part II of COS- LC (figure 3). Smoking causes 
approximately 90% of all lung cancers and on a societal 
level smokers are often blamed for their lung cancer, 
which can lead to feelings of self- blame and guilt.27 This 
could explain the tendency towards long- term negative 
psychosocial consequences in the lung cancer- specific 
scales: self- blame, focus on airway symptoms and harm 
of smoking in part I. In contrast, no negative long- term 
consequences were seen in the remaining six scales in part 
I. There might be several explanations for our findings: 
(1) the true- positive group had a more positive psycho-
social profile at baseline than the other groups. Hence, 
no long- term differences compared with the control 
group were seen, when the short- term negative psycho-
social consequences diminished with time towards the 
more positive set point; (2) selection bias was identified 
among DLCST participants, who were better educated 
and with a more positive psychosocial profile compared 
with a matched background population.28 Thus, DLCST 
participants were probably more psychosocially robust 
than average and therefore false- positive or true- positive 
findings might have had fewer negative consequences 
than could be expected for the general population; (3) 
those diagnosed with lung cancer via screening and who 
remained alive and asymptomatic after 18 months were 
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Table 1 Characteristics of participants
Total
n=630
CT group n=382 Control group n=248
True negative False positive True positive P value* Missing
n=252 n=91 n=39 n=248   
Round, n (%) 0.543 0
2 158 (25.1) 68 (27.0) 26 (28.6) 9 (23.1) 55 (22.2)
3 196 (31.1) 76 (30.2) 24 (26.4) 14 (35.9) 82 (33.1)
4 76 (12.1) 31 (12.3) 10 (11.0) 8 (20.5) 27 (10.9)
5 200 (31.8) 77 (30.6) 31 (34.1) 8 (20.5) 84 (33.9)
Sex, n (%) 0.174 0
Men 298 (47.3) 118 (46.8) 37 (40.7) 24 (61.5) 119 (48.0)
Women 332 (52.7) 134 (53.2) 54 (59.3) 15 (38.5) 129 (52.0)
Age (years), median 
(IQR)
58 (55–62) 58 (55–62) 58 (54–61) 60 (58–65) 59 (55–62) 0.017 0
Social group, n (%) 0.334 1
I 42 (6.7) 23 (9.2) 3 (3.3) 1 (2.6) 15 (6.1)
II 132 (21.0) 51 (20.3) 13 (14.3) 9 (23.1) 59 (23.8)
III 126 (30.0) 53 (21.1) 15 (16.5) 6 (15.4) 52 (21.0)
IV 158 (25.1) 57 (22.7) 28 (30.8) 13 (33.3) 60 (24.2)
V 81 (12.9) 29 (11.6) 13 (14.3) 6 (15.4) 33 (13.3)
Employed, social 
group uncertain
54 (8.6) 21 (8.4) 12 (13.2) 1 (2.6) 20 (8.1)
Outside the labour 
market
36 (5.7) 17 (6.8) 7 (7.7) 3 (7.7) 9 (3.6)
School education, n 
(%)
0.321 0
7–9 years in school 242 (38.4) 88 (34.9) 45 (49.5) 16 (41.0) 93 (37.5)
10 years in school 229 (36.4) 99 (39.3) 27 (29.7) 15 (38.5) 88 (35.5)
11–13 years in school 159 (25.2) 65 (25.8) 19 (20.9) 8 (20.5) 67 (27.0)
Employment status, 
n (%)
0.219 1
Employed 374 (59.5) 158 (62.7) 48 (52.8) 18 (47.4) 150 (60.5)
Studying 2 (0.3) 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.4)
Job seeking 35 (5.6) 17 (6.8) 7 (7.7) 3 (7.9) 8 (3.2)
Retired 218 (34.7) 77 (30.6) 35 (38.5) 17 (44.7) 89 (35.9)
Region of residence, n (%) 0.043 1
Capital Region 522 (83.0) 310 (83.3) 70 (76.9) 32 (82.1) 210 (85.0)
Region Zealand 98 (15.6) 34 (13.5) 20 (22.0) 7 (18.0) 37 (15.0)
Region of Southern 
Denmark
9 (1.4) 8 (3.2) 1 (1.1) 0 (0.0) 0 (0.0)
Living alone, n (%) 0.147 4
No 430 (68.7) 175 (69.7) 54 (59.3) 25 (64.1) 176 (71.8)
Yes 196 (31.3) 76 (30.3) 37 (40.7) 14 (35.9) 69 (28.2)
Smoking status, n (%) 0.195 0
Current smoker 473 (75.1) 183 (72.6) 72 (79.1) 34 (87.2) 184 (74.2)
Former smoker 157 (24.9) 69 (27.4) 19 (20.9) 5 (12.8) 64 (25.8)
Smoking history (pack 
years), median (IQR)
34 (27–43) 34 (27–43) 34 (27–43) 43 (34–49) 33 (26–42) 0.001 1
Charlson Comorbidity Index, n (%) 0.913 0
Continued
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Total
n=630
CT group n=382 Control group n=248
True negative False positive True positive P value* Missing
n=252 n=91 n=39 n=248   
0 590 (93.7) 235 (93.3) 83 (91.2) 36 (92.3) 236 (95.2)
1 25 (4.0) 10 (4.0) 5 (5.5) 2 (5.1) 8 (3.2)
≥2 15 (2.4) 7 (2.8) 3 (3.3) 1 (2.6) 4 (1.6)     
*P value of a Pearson’s χ2 test (categorical variables) or a Kruskal- Wallis test (continuous variables); p values are estimates of the exact p 
values based on 10 000 Monte Carlo simulations under the null- hypothesis.
Table 1 Continued
Table 2 Conditional likelihood ratio (CLR) fit statistics and 
Cronbach’s alpha for the 15 domains of the Consequences 
of Screening in Lung Cancer questionnaire
Scales (no. of items) CLR df P value*
Cronbach’s 
α
Anxiety (7) 23.0 20 0.286 0.903
Behaviour (7) 19.0 20 0.520 0.893
Dejection (6) 14.9 17 0.603 0.916
Negative impact on 
sleep (4)
22.3 11 0.022 0.874
Self- blame (5) 20.2 14 0.124 0.962
Focus on airway 
symptoms (2)
1.0 5 0.966 0.802
Stigmatisation (4) 24.6 11 0.010 0.916
Introvert (4) 11.2 11 0.425 0.851
Harm of smoking (2) 9.8 5 0.082 0.857
Existential values (6) 9.3 11 0.591 0.851
Calm/Relaxed (2) 0.6 3 0.887 0.693
Social network (3) 5.5 5 0.362 0.754
Impulsivity (6) 4.5 11 0.954 0.854
Empathy (3) 5.9 5 0.314 0.699
Regretful about still 
smoking (4)
1.0 7 0.795 0.863
*After adjustment for multiple testing by using the methods of 
Benjamini- Hochberg, the level of statistical significance was 
assessed at 0.0033.
convinced, they had been cured of a lethal disease. This 
reassurance is likely since lung cancer symptom lead 
time is longer than 18 months and a minimum of 20% 
of screening detected lung cancers are overdiagnosed.29 
If those diagnosed with lung cancer via screening do not 
experience any substantial long- term negative psychoso-
cial consequences, it is not expected that the experiences 
of other screening groups will differ; (4) another expla-
nation for the long- term results could be the fact that 
the control group experienced more negative psychoso-
cial consequences than the CT group through screening 
rounds 2–5 in DLCST.30 The level of psychosocial conse-
quences in the control group was therefore more negative 
(higher COS- LC scores), which decreases the difference 
between the control group and the positive CT screening 
groups; (5) during the development of the COS- LC, the 
qualitative interviews were conducted 0–5 months after 
screening; therefore, part II of the COS- LC might not 
capture all relevant long- term psychosocial consequences 
for those with false- positive findings; (6) approximately 
20% of the participants who received a positive screening 
result had previously received a false- positive result. 
Participants might therefore become accustomed to 
receiving a (false- )positive screening result, which could 
decrease the level of negative psychosocial consequences. 
In contrast, the COS- LC was developed in the first round 
and a first- round effect, which most likely would have had 
a more negative psychosocial impact on the participants, 
was not seen; (7) contamination of the control group 
could have biassed our results; nevertheless, contamina-
tion of the DLCST was found to be minor31; (8) partic-
ipants with false- positive results could have received a 
negative screening result between the 6- month and the 
18- month assessments, which could be perceived as reas-
surance, consequently lowering the negative psychosocial 
consequences.
This is the first study to present both short- term and 
long- term psychosocial consequences of false- positive 
results using a lung cancer- specific questionnaire with 
high content validity and adequate psychometric proper-
ties developed in a randomised controlled lung cancer 
CT screening trial. Therefore, the COS- LC most likely 
presents stronger results compared with generic ques-
tionnaires. The true- positive group was included in this 
study and when both the true- positive and the true- 
negative groups are included, the extent of the psycho-
social harm in the false- positive group can be compared 
with the extent of harm in those who should be worst off 
(true positives) and those who are reassured (true nega-
tives). No significant differences were shown, however, in 
the long- term psychosocial consequences for either the 
false- positive group or the true- positive group compared 
with the control group.
Other quantitative studies have investigated the health- 
related quality of life (HRQoL) in CT screening using 
generic questionnaires that have not been validated for 
lung cancer.13 19–21 Although one lung cancer- specific 
questionnaire was used, no information about validation 
was reported.19 These studies found that CT screening 
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Figure 2 The mean score of the nine psychosocial outcomes of Consequences of Screening in Lung Cancer (COS- LC) 
part I for the diagnostic groups and the control group in the Danish Lung Cancer Screening Trial at five time points: baseline, 
1 week, 1, 6 and 18 months. The means of COS- LC part I scales are compared between all groups at each time point and 
significant differences between the groups are described below each scale (see online supplementary appendix 1 for details 
of the adjusted analyses). After adjustment for multiple testing by the method of Benjamini- Hochberg, the level of statistical 
significance was assessed at 0.0043; 0=baseline; 1 w=1 week after screening; 1 m, 6 ms and 18 ms=1, 6 and 18 months after 
final diagnostic result; the higher the score the more negative psychosocial reaction.
had only short- term and no long- term negative effects 
on HRQoL for participants with false- positive results. 
Our study, using a more accurate and validated survey 
instrument, has confirmed this. However, the absence of 
long- term psychosocial consequences in the true- positive 
group as well suggests that certain long- term conse-
quences may have been overlooked or that the develop-
ment of a certain resilience or relief (at feeling cured) 
may play a long- term role.32
A study investigating the risk of receiving a prescription 
on antidepressants or anxiolytics in the CT group (mixed 
negative and positive results) compared with the control 
group in DLCST found no differences between these 
groups.33 These outcomes measure extremes of psycho-
social consequences, which is a plausible explanation for 
the negative results. However, another study, which inves-
tigated healthcare use and costs in DLCST participants 
showed higher use of the healthcare system among false 
positives and true positives compared with the control 
group in the time period between two screening rounds.15 
This may be associated with an increased attention drawn 
to the risk of not being healthy subsequent to receiving 
a false- positive result. A meta- analysis of the psychosocial 
consequences of false- positive mammograms including 
both generic and condition- specific outcome measures 
showed both short- term and long- term (up to 3 years) 
negative psychosocial consequences compared with true- 
negative mammograms.12 34 This study recommends 
the use and further development of condition- specific 
measures instead of generic measures in mammography 
screening. Condition- specific measures should also be 
improved and used in lung cancer CT- screening to obtain 
the most valid results for psychosocial outcomes.
In interpreting the effect size of the results, we used 
the mean increase of 2.16 in self- blame in the false- 
positive group at the 1 month time point compared with 
the control group (online supplementary appendix 3). 
This increase corresponds to two shifts in the response 
category of one item for all participants with false- positive 
results, for example, from ‘not at all’ to ‘quite a bit’, while 
all the participants in the control group had no shift in 
response category. The false- positive rates differ substan-
tially in the NLST (23%) and the DLCST (3%), which 
has been discussed in detail previously.15 The negative 
consequences may seem small or transient in relative 
terms; however, in absolute terms they might be large. 
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Figure 3 The mean score of the six psychosocial outcomes of Consequences of Screening in Lung Cancer (COS- LC) part 
II for the diagnostic groups in the Danish Lung Cancer Screening Trial at three time points: 1, 6 and 18 months. The means of 
COS- LS Part II scales are compared between the three screened groups at each time point after the final diagnostic result and 
significant differences between the groups are described below each scale (see online supplementary appendix 1 for details 
of the adjusted analyses). After adjustment for multiple testing by the method of Benjamini- Hochberg, the level of statistical 
significance was assessed at 0.0043; 0=baseline; 1 w=1 week after screening; 1 m, 6 ms and 18 ms=1, 6 and 18 months after 
final diagnostic result; the higher the score the more psychosocial reaction.
There are two reasons for this: first, a mass screening 
programme targeting a large population, a small change 
in the frequency with which they appear, may be a large 
increase in the absolute number of presumably healthy 
people affected by these consequences; second, the posi-
tive predictive value (PPV) of an abnormal low- dose CT 
screening result might be much lower in an ongoing 
screening programme compared with the PPV obtained 
in a research setting, for example, in the Veterans Health 
Administration in the USA there was nearly a false- 
positive rate of 60% in their first screening round.35 
This will also increase the costs even more. We have in 
previous research shown that low- dose CT screening for 
lung cancer will in a Danish context with a public funded 
healthcare system increase total health costs by 60%16 and 
specifically for those with false- positive results the cost will 
increase by 66%.15 The knowledge of psychosocial conse-
quences from false- positive results contributes to the 
evidence for the benefits and harms of lung cancer CT 
screening and should be included in the overall assess-
ment of the European trials.
COnCluSIOn
In the DLCST, false- positive results were associated with 
more negative short- term psychosocial consequences 
compared with the control group and the true- negative 
group.
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